RNS Number : 0246A
Fevara PLC
13 April 2026
13 April 2026
Fevara plc
("Fevara", the "Company" or the "Group")
Notice of Investor Presentation
Fevara plc (LSE: FVA), an international specialist in livestock supplements, will host a live presentation for investors in respect of the Company's results for the six months ended 28 February 2026.
Joshua Hoopes, Chief Executive Officer and Gavin Manson, Chief Financial Officer, will provide a live presentation via the Engage Investor platform at 11.00am BST on Friday 24 April 2026.
Fevara PLC welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation. Investors can sign up to Engage Investor at no cost and follow Fevara PLC from their personalised investor hub.
Register your interest in this event here: https://engageinvestor.news/FVA_IP26
- Ends -
For further information, please contact:
Enquiries
About Fevara plc:
Fevara is an international specialist in livestock supplements.
Fevara's purpose is to empower farmers in extensive grazing systems with research-proven products that boost profitability, improve resource efficiency and support sustainable agriculture. The Group develops, manufactures and markets research-proven supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses, sold under recognised and trusted brands, including Crystalyx®, Horslic®, Horslyx®, Scotmin Nutrition®, SmartLic®, Tracesure® Advanced and Macal®.
Headquartered in Carlisle, Cumbria, in the UK, Fevara has six manufacturing sites in the UK, US and Brazil with three operational joint ventures in Germany and the US. It serves customers in more than 20 countries through its expansive international distribution and support network.
Fevara has been listed on the London Stock Exchange since 1972.
For more information, visit: www.fevara.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAURARRNOUSAAR
